LaFleur & Godfrey LLC buys 3,570 shares of Johnson & Johnson (NYSE:JNJ)

LaFleur & Godfrey LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 131,689 shares of the company’s stock after purchasing an additional 3,570 shares during the quarter. Johnson & Johnson comprises about 2.8% of LaFleur & Godfrey LLC’s investment portfolio, making the stock its 7th largest holding. LaFleur & Godfrey LLC’s holdings in Johnson & Johnson were worth $19,248,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Christopher J. Hasenberg Inc purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $31,000. WFA Asset Management Corp lifted its position in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares in the last quarter. MFA Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $43,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $45,000. Hedge funds and other institutional investors own 69.55% of the company’s shares.

Johnson & Johnson stocks rose 1.1%

NYSE JNJ opened at $164.10 on Friday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $167.78. The company has a quick ratio of 0.85, a current ratio of 1.07, and a debt-to-equity ratio of 0.44. The company’s fifty-day simple moving average is $153.92, and its 200-day simple moving average is $153.27. The firm has a market cap of $394.94 billion, a PE ratio of 10.23, a P/E/G ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ – Get Free Report ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue rose 4.3% year over year. During the same period in the previous year, the firm earned $2.80 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson announces dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, August 27. This represents an annualized dividend of $4.96 and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Changes in Analyst Ratings

JNJ has been the subject of several recent analyst reports. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the company from $160.00 to $150.00 in a research report on Tuesday. July 23. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Goldman Sachs Group cut their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, 18 July. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Moderate Buy” and a consensus price target of $173.21, based on data from MarketBeat.

Get the latest stock report on JNJ

Johnson & Johnson profile

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Further reading

Want to see what other hedge funds JNJ owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Free Report).

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.